Search

Immunocore Holdings PLC ADR

Cerrado

37.06 0.98

Resumen

Variación precio

24h

Actual

Mínimo

34.58

Máximo

37.29

Métricas clave

By Trading Economics

Ingresos

-14M

-786K

Ventas

9.3M

116M

BPA

-0.02

Margen de beneficios

-0.678

Empleados

524

EBITDA

-13M

3.6M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+71.62% upside

Dividendos

By Acuity

Próximas Ganancias

5 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

236M

1.9B

Apertura anterior

36.08

Cierre anterior

37.06

Immunocore Holdings PLC ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 ago 2026, 20:07 UTC

Immunocore Holdings PLC shares are higher amid positive market sentiment. The overall market benefits from declining oil prices and lower Treasury yields.

24 ago 2026, 20:06 UTC

Immunocore Holdings PLC shares are lower amid rising oil prices and geopolitical tensions, including new U.S. sanctions against Iran. No specific company news was identified.

21 ago 2026, 19:46 UTC

News

IMCR gains as JPMorgan reinstates coverage with Overweight rating.

20 ago 2026, 20:02 UTC

Immunocore Holdings PLC shares are lower today, reflecting declines in the Biotechnology sub-sector. The stock has shown notable volatility during the session.

19 ago 2026, 22:51 UTC

Immunocore Holdings PLC shares are higher in after-market hours, continuing an upward trend. No specific news was identified to explain the movement.

18 ago 2026, 20:01 UTC

Immunocore Holdings PLC is rising amid biotechnology sector strength, despite pulling back from an earlier session high. No specific company news was identified.

17 ago 2026, 19:23 UTC

News

Immunocore Holdings PLC shares are higher today following HC Wainwright's improved Q3 2026 earnings estimates, raising loss per share projections to -$0.08 from -$0.25.

14 ago 2026, 22:16 UTC

Immunocore Holdings PLC shares are lower in after-market trading. Broader market sentiment is impacted by declining retail sales and consumer confidence.

11 ago 2026, 20:01 UTC

Immunocore Holdings PLC is rising as biotechnology sector strength supports shares, though the stock has pulled back from an earlier session high.

10 ago 2026, 19:16 UTC

News

Immunocore Holdings PLC reports second-quarter revenue of $115.93 million, with shares lower amid broader market trends and declining U.S. stock futures.

7 ago 2026, 20:04 UTC

News

Immunocore Holdings reported a wider Q2 loss of 2 cents per share and $115.9 million in revenue, with shares trading lower since Thursday's close.

6 ago 2026, 19:52 UTC

News

Immunocore Holdings PLC reported Q2 earnings of -$0.02 per share and revenue of $115.93 million, exceeding expectations. Shares are trading higher during Thursday's session.

5 ago 2026, 20:02 UTC

Immunocore Holdings PLC is higher today, reflecting broader gains in the Biotechnology sector. No specific company news was identified to explain the movement.

4 ago 2026, 19:51 UTC

Immunocore Holdings PLC shares are higher today amid broader market strength and a notable decline in crude oil prices, easing inflation concerns.

3 ago 2026, 20:03 UTC

News

Immunocore Holdings PLC is declining in Monday's session, diverging from gains in major tech stocks and remaining below its 20-day moving average.

31 jul 2026, 20:06 UTC

Immunocore Holdings PLC shares are lower today, with no specific news identified. The stock has fluctuated within a routine range during the session.

28 jul 2026, 19:56 UTC

Immunocore Holdings PLC shares are lower today, continuing a three-session decline amid broader market sentiment influenced by declines in Asian markets.

27 jul 2026, 18:06 UTC

Immunocore Holdings PLC shares are lower today, reflecting a broader market trend amid a significant decline in oil prices. No specific company news was identified.

24 jul 2026, 15:26 UTC

Immunocore Holdings PLC shares are lower today, having declined from a session high. This movement occurs amid mixed labor market data and inflation concerns.

22 jul 2026, 19:16 UTC

News

Immunocore Holdings PLC shares are higher as Wall Street Zen upgraded its rating to "buy," despite a mixed analyst outlook.

21 jul 2026, 21:01 UTC

Immunocore Holdings PLC shares are higher in after-market trading, driven by optimistic sentiment in U.S. markets and better-than-expected results from major companies.

20 jul 2026, 20:06 UTC

News

Immunocore Holdings PLC shares are lower amid broader market weakness. Analyst ratings show mixed sentiment, with upgrades and downgrades influencing performance.

Comparación entre iguales

Cambio de precio

Immunocore Holdings PLC ADR previsión

Precio Objetivo

By TipRanks

71.62% repunte

Estimación a 12 Meses

Media 62.83 USD  71.62%

Máximo 100 USD

Mínimo 35 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Immunocore Holdings PLC ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

4

Comprar

2

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
help-icon Live chat